In the systematic review, we identified only a single study that evaluated the prognostic value of S-EGFR in early-stage breast cancer patients, which included only 119 patients20, and we found no studies that evaluated the prognostic or predictive value of any of the EGFR ligands in early-stage breast cancer patients16. This evidence concerns the gene EGFR and breast cancer.